OTC boost for China Pharma
This article was originally published in The Tan Sheet
China Pharma Holdings' 2008 net income grows 39 percent to $17.8 million due to a 76.6 percent sales increase of OTC cold and flu product PuSen OK (naproxen and pseudophedrine), the only generic version of Bayer's Aleve-D in China. Located in Haikou, the capital of the Hainan province, China Pharma markets 18 products treating infectious diseases, flu/cold and cardiovascular disease and makes nutritional supplements and traditional Chinese medicine, according to a March 17 release. The company is developing generic drugs for off-patent blockbuster drugs but is shifting to an innovative biopharmaceutical enterprise through the products in its pipeline
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.